Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.41 |
| ▸ | CTSD | P07339 | 9/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693114 | 1.00 | BACE1 (0.41) | BACE1CTSDBACE2 | |
| SCHEMBL5223477 | 0.87 | BACE1 (0.44) | BACE1CTSDBACE2 | |
| SCHEMBL5223435 | 0.87 | BACE1 (0.42) | BACE1CTSDBACE2 | |
| SCHEMBL5223476 | 0.87 | BACE1 (0.44) | BACE1CTSDBACE2 | |
| SCHEMBL5220282 | 0.83 | BACE1 (0.39) | BACE1CTSDBACE2 | |
| SCHEMBL5220292 | 0.83 | BACE1 (0.39) | BACE1CTSDBACE2 | |
| SCHEMBL5219187 | 0.82 | SIGMAR1 (0.43) | BACE1 | |
| SCHEMBL5219195 | 0.82 | SIGMAR1 (0.43) | BACE1 | |
| SCHEMBL5223463 | 0.80 | OPRD1 (0.41) | BACE1 | |
| SCHEMBL5223473 | 0.80 | OPRD1 (0.41) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692143-B1 | TRICYCLIC INDOLE HYDROXYETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20070073060-A1 | Tricycle indole hydroxyethlamine derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073060-A1 | Tricycle indole hydroxyethlamine derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, APP | BACE1 2/4885CTSD 253/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.